Stockscreener 앱 받기
9.74
0.71%
-0.07
시간 외 거래:
9.80
0.06
+0.62%
전일 마감가:
$9.81
열려 있는:
$9.68
하루 거래량:
3.82M
Relative Volume:
0.80
시가총액:
$2.49B
수익:
$885.72M
순이익/손실:
$-457.98M
주가수익비율:
-5.4827
EPS:
-1.7765
순현금흐름:
$293.05M
1주 성능:
+3.84%
1개월 성능:
+0.00%
6개월 성능:
+44.08%
1년 성능:
+15.27%
1일 변동 폭
$9.46
$9.7999
1주일 범위
$9.2801
$10.68
52주 변동 폭
$6.00
$11.22
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.74 | 2.71B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 재개 | Evercore ISI | Outperform |
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan
Research Analysts Issue Forecasts for BCRX Q4 Earnings - marketbeat.com
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - marketbeat.com
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance
A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - marketbeat.com
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside - DirectorsTalk Interviews
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
Weekly Recap: Q2 revenue jump, raised guidance and Astria R&D charge, shift - TradingView
BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen - marketbeat.com
BCRX SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus
BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain - Yahoo! Finance Canada
State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing - Stock Titan
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors - Sahm
BCRX Maintained by RBC Capital -- Price Target Lowered to $13.00 - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
BCRX Maintained by Wedbush -- Price Target Lowered to $20.00 - GuruFocus
BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure - WBMA
Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - marketbeat.com
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-08-06 - Seeking Alpha
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Pacer Advisors Inc. Makes New $14.88 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
Q2 2026 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call High - GuruFocus
BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingView
Astria deal drives large H1 loss at BioCryst Pharmaceuticals (Nasdaq: BCRX) - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating - Yahoo Finance
Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook - Investing.com
BioCryst Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
BioCryst Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com
BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised - marketscreener.com
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is BioCryst Pharmaceuticals Inc (BCRX) Undervalued After Q2 Earn - GuruFocus
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
5.15%
자본화:
|
볼륨(24시간):